Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
« Previous episode: AI in stroke
Next episode: Disease-modifying therapy for type 1 diabetes »